SFSIG
ALNY icon

San Francisco Sentry Investment Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

San Francisco Sentry Investment Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-11
Closed -$1K – 672
2020
Q1 		$1K Hold
11
– – ﹤0.01% 706
2019
Q4 		$1K Hold
11
– – ﹤0.01% 795
2019
Q3 		$1K Buy
+11
New +$870 ﹤0.01% 797
2018
Q4 		– Sell
-10
Closed -$1K – 979
2018
Q3 		$1K Buy
+10
New +$1.01K ﹤0.01% 836

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

San Francisco Sentry Investment Group's ALNY Position: Q2 2020 in Review

San Francisco Sentry Investment Group sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2020, closing a stake of 11 shares — an estimated $1K sold.

San Francisco Sentry Investment Group first reported a position in ALNY in Q3 2018 and held it in 4 quarters. The position peaked at $1K in Q1 2020. 375 funds tracked by Wall St. Rank hold ALNY as of Q2 2020.

  • San Francisco Sentry Investment Group reported no remaining Alnylam Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • San Francisco Sentry Investment Group sold 11 Alnylam Pharmaceuticals shares in Q2 2020, an estimated $1K.
  • San Francisco Sentry Investment Group first reported a position in Alnylam Pharmaceuticals in Q3 2018 and held it in 4 quarters.
  • San Francisco Sentry Investment Group's Alnylam Pharmaceuticals position peaked at $1K in Q1 2020.
  • 375 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2020.

Based on San Francisco Sentry Investment Group's 13F filing for Q2 2020, filed 17 Jul 2020.